News

Acute Hepatitis E Superinfection Reactivates Chronic HBV

When a patient presents with a significant flare up of chronic HBV infection, the clinicians find an unexpected possible cause.


 

Many things can reactivate chronic hepatitis B virus (HBV) infection—withdrawal of antiviral therapy, pregnancy, and chemotherapy, to name a few. So when a patient with stable chronic HBV virus presented with significant hepatitis flare, clinicians from Beth Israel Deaconess Medical Center in Boston, Massachusetts, had a long list to check.

They first ruled out drug-associated hepatotoxicity and screened the patient for common causes of acute hepatitis. Beyond the HBV, the patient did not have other significant medical conditions, had not had close contact with anyone ill, and was not pregnant. Tests were negative for cytomegalovirus, Epstein-Barr syndrome, HIV, hepatitis A, C, and D. The patient tested negative for both antihepatitis E virus (HEV) IgM and IgG in a visit about 9 months before.

However, she reported regularly consuming pork, including a recent barbecue meal. Thus, the clinicians focused on HEV serology, which confirmed that she had an acute HEV infection.

Pigs act as a “natural reservoir” for HEV; contaminated meats and direct contact with animals are the most common causes of HEV human infection in industrialized countries. Recent data reveal the prevalence of HEV antibodies in the US is about 6%, illustrating that it is not as uncommon as it was thought to be. Although there was no direct evidence to confirm the source of her infection, it seemed likely due to the pork consumption.

The patient was started on tenofovir but stopped it 4 months later because she felt well. After a subsequent flare, “repeated counseling” persuaded the patient to start on entecavir, with successful viral suppression.

Hepatitis E superinfection on chronic HBV can contribute to significant morbidity and mortality, the clinicians say, particularly in patients with cirrhosis. Concurrent infection with another viral hepatitis should be considered in both immunodeficient and immunocompetent patients with chronic HBV reactivation.

Source:

Aslam A, Susheela A, Iriana S, Chan SS, Lau D. BMJ Case Rep. 2018;2018. pii: bcr-2017-223616.
doi: 10.1136/bcr-2017-223616.

Recommended Reading

Open Clinical Trials for Patients With HIV and/or Hepatitis B and C (FULL)
Federal Practitioner
Improving Veteran Access to Treatment for Hepatitis C Virus Infection (FULL)
Federal Practitioner
Strategies to Improve Hepatocellular Carcinoma Surveillance in Veterans With Hepatitis B Infection (FULL)
Federal Practitioner
Heart Transplantation Outcomes in Patients With Hepatitis C Virus Infection: Potential Impact of Newer Antiviral Treatments After Transplantation (FULL)
Federal Practitioner
HCV Patient on Tacrolimus? Keep an Eye on RBCs
Federal Practitioner
How to choose between highly effective HBV therapies
Federal Practitioner
CKD triples risk of bad outcomes in HIV
Federal Practitioner
VIDEO: Hepatitis C eradication cuts nonliver cancer rate
Federal Practitioner
Hepatitis A Outbreak in a Childcare Facility
Federal Practitioner
HCV incidence is elevated in HIV-positive MSM
Federal Practitioner